ELOA

Across TCGA pan-cancer cohorts, ELOA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ELOA data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ELOA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELOA expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

HNSC, UCEC, and GBM are the cancer types where ELOA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.634	0.939	<.001	15	view →
UCEC	DFS	Tertile	All	1.000	0.908	.024	8	view →
GBM	DFS	Tertile	All	0.281	0.431	.016	7	view →
LSCC	OS	Quartile	II,III,IV	0.872	0.550	.021	5	view →
CCRCC	OS	Quartile	III,IV	0.478	0.861	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ELOA–HNSC (DFS)

Open the HNSC breakdown →